The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

A preoperative trial shows that activating the progesterone receptor with low-dose megestrol can deepen estrogen blockade and curb tumor proliferation, without added toxicity, pointing to a simpler ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

BOSTON — The risk for local recurrence of breast cancer decreases as event-free survival lengthens, according to an analysis of a large database from the Netherlands. The study, which also ...

Inluriyo is approved for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after prior endocrine therapy failure. The EMBER-3 trial showed Inluriyo reduced cancer progression or death ...

Findings showed giredestrant led to a statistically significant and clinically meaningful improvement in iDFS vs physician’s choice of endocrine therapy at the pre-planned interim analysis. Topline ...

Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...

—There was no significant difference in invasive disease-free survival between patients with human epidermal growth factor receptor 2-positive (HER2+) T1micN0 breast cancer who were and were not ...